日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study

皮下注射Lenacapavir治疗多重耐药HIV-1感染者:CAPELLA研究的156周结果

Ogbuagu, Onyema; Wiznia, Andrew; McGowan, Joseph P; Berger, Daniel S; Creticos, Catherine M; Hagins, Debbie; Hodge, Theo; Osiyemi, Olayemi; Sims, James; Wheeler, David A; Wang, Hui; Margot, Nicolas A; Dvory-Sobol, Hadas; Rhee, Martin S; Segal-Maurer, Sorana; Molina, Jean-Michel

Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants

利那卡帕韦对人类免疫缺陷病毒2型(HIV-2)分离株和耐药HIV-2突变株的抗病毒活性

Smith, Robert A; Raugi, Dana N; Nixon, Robert S; Seydi, Moussa; Margot, Nicolas A; Callebaut, Christian; Gottlieb, Geoffrey S

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

体外表征 HIV-1 对替诺福韦艾拉酚胺的耐药性

Margot Nicolas A, Johnson Audun, Miller Michael D, Callebaut Christian

Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations

人类免疫缺陷病毒1型逆转录酶在第69位残基后插入二丝氨酸以及多种胸苷类似物相关突变所赋予的替诺福韦耐药性的分子机制

White, Kirsten L; Chen, James M; Margot, Nicolas A; Wrin, Terri; Petropoulos, Christos J; Naeger, Lisa K; Swaminathan, S; Miller, Michael D